We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Study of PM060184 in Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01299636
Recruitment Status : Completed
First Posted : February 18, 2011
Last Update Posted : November 2, 2015
Information provided by (Responsible Party):

Brief Summary:
The purpose of the study is to determine the maximum tolerated dose and the recommended dose and to evaluate the safety and tolerability of PM060184.

Condition or disease Intervention/treatment Phase
Solid Tumors Drug: PM060184 Phase 1

Detailed Description:
This trial intends to determine the maximum tolerated dose and the recommended dose, to evaluate the safety and tolerability, to determine the pharmacokinetics and to evaluate the antitumor activity of PM060184 in patients with advanced solid tumors.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM060184 Administered Intravenously to Patients With Advanced Solid Tumors
Study Start Date : January 2011
Primary Completion Date : August 2015
Study Completion Date : August 2015

Arm Intervention/treatment
Experimental: PM060184 Drug: PM060184
PM060184 administered intravenously (i.v.) over 10 minutes at a starting dose of 4 mg/m2/day on three consecutive days q2w (on Days 1-3 and 15-17) every 28 days.

Primary Outcome Measures :
  1. MTD (maximum tolerated dose) and RD (recommended dose) of PM060184. [ Time Frame: From treatment onset to end of treatment ]
    To determine the maximum tolerated dose (MTD) and the recommended dose (RD) of PM060184 administered on Days 1 and 8 of a 21-day cycle intravenously (i.v.) over 10 minutes to patients with advanced solid tumors.

Secondary Outcome Measures :
  1. To determine the pharmacokinetics of this drug in patients who have advanced solid tumors. [ Time Frame: Blood samples will be collected up to 48 hours after the first infusion. At the RD, 24-h urine collection samples and 15 additional blood samples up to 48 hours after the second infusion of the first cycle. ]
    The complete plasma concentration-time profiles of PM06184 will be analyzed by standard non-compartmental methods.The percent of PM060184 total dose excreted unchanged into the urine over the collection interval will be calculated from the urine samples.

  2. Antitumor activity [ Time Frame: Every six weeks while on treatment. Patients who discontinued treatment without disease progression will be followed every three months until disease progression, other antitumor therapy, death or until the end-of-study date, whichever occurs first. ]
    Antitumor activity will be measured according to the RECIST (Response Evaluation Criteria In Solid Tumors) version 1.1 or by evaluation of tumor markers

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria

  1. Voluntary signed and dated written informed consent.
  2. Patients with advanced solid tumors refractory to Standard therapy.
  3. Age >/= 18 years.
  4. Recovery from drug-related adverse events (AEs) of previous treatments, excluding alopecia.
  5. Normal laboratory values within seven days prior to treatment administration.
  6. Women of childbearing potential must have a negative serum pregnancy test before study entry. Both men and women must agree to use a medically acceptable method of contraception throughout the treatment period and for three months after discontinuation of treatment.

Exclusion criteria

  1. Pregnant or lactating women.
  2. Less than three weeks from radiation therapy or last dose of hormonal therapy, biological therapy or chemotherapy
  3. Prior treatment with any investigational product less than 30 days prior to the first.
  4. Central Nervous System metastases
  5. Other relevant diseases or adverse clinical conditions:

    • Increased cardiac risk:
    • Presence of significant neurological or psychiatric disorders
    • Neuropathy
    • Active infection requiring treatment.
    • Liver disease (e.g., cirrhosis, hepatitis).
    • Immunocompromised patients.
    • Any other major illness.
  6. Limitation of the patient's ability to comply with the treatment.
  7. Known hypersensitivity to any of the components of the drug product.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01299636

United States, Texas
START- South Texas Accelerated Research Therapeutics, LLC
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Principal Investigator: Kyriakos Papadopoulos, MD START- South Texas Accelerated Research Therapeutics, LLC

Responsible Party: PharmaMar
ClinicalTrials.gov Identifier: NCT01299636     History of Changes
Other Study ID Numbers: PM60184-A-002-10
First Posted: February 18, 2011    Key Record Dates
Last Update Posted: November 2, 2015
Last Verified: October 2015

Keywords provided by PharmaMar:
Phase I
Pharma Mar